Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy

類似資料

• Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib
  著者:: Amin, Syed O., 等
  出版事項: (2020)
• Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib
  著者:: Singh, Anand Prakash, 等
  出版事項: (2020)
• Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
  著者:: Tanneeru, Karunakar, 等
  出版事項: (2013)
• Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
  著者:: Marin, David, 等
  出版事項: (2012)
• The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear
  著者:: Loren, Cassandra P., 等
  出版事項: (2014)